Login to Your Account



EMEA Finds More Tysabri PMLs; Squeezes Key Market Overseas

By Jennifer Boggs


Monday, October 26, 2009
Shares of Biogen Idec Inc. and partner Dublin, Ireland-based Elan Corp. plc took a hit Friday after news of a European review disclosed a higher number of PML cases linked to multiple sclerosis drug Tysabri (natalizumab) than previously reported. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription